ECSP088375A - Alquil sulfóxido quinolinas como ligandos del receptor nk-3 - Google Patents

Alquil sulfóxido quinolinas como ligandos del receptor nk-3

Info

Publication number
ECSP088375A
ECSP088375A EC2008008375A ECSP088375A ECSP088375A EC SP088375 A ECSP088375 A EC SP088375A EC 2008008375 A EC2008008375 A EC 2008008375A EC SP088375 A ECSP088375 A EC SP088375A EC SP088375 A ECSP088375 A EC SP088375A
Authority
EC
Ecuador
Prior art keywords
sulfóxido
quinolinas
legandos
rent
del receptor
Prior art date
Application number
EC2008008375A
Other languages
English (en)
Inventor
Jeffrey S Albert
Gerard M Koether
Cristobal Alhambra
James Kang
Thomas R Simpson
James Woods
Yan Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37889114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088375A publication Critical patent/ECSP088375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de la Fórmula (I), en donde R1, A, R2, R3, R4, R5, n, m y q son tal como se indica en la descripción, sales farmacéuticamente aceptables, métodos para su preparación, composiciones farmacéuticas que los contienen y métodos para utilizarlos.
EC2008008375A 2005-09-21 2008-04-16 Alquil sulfóxido quinolinas como ligandos del receptor nk-3 ECSP088375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71928605P 2005-09-21 2005-09-21
US71927505P 2005-09-21 2005-09-21

Publications (1)

Publication Number Publication Date
ECSP088375A true ECSP088375A (es) 2008-05-30

Family

ID=37889114

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008375A ECSP088375A (es) 2005-09-21 2008-04-16 Alquil sulfóxido quinolinas como ligandos del receptor nk-3

Country Status (17)

Country Link
US (1) US7964733B2 (es)
EP (1) EP1928835B1 (es)
JP (1) JP2009508946A (es)
KR (1) KR20080046669A (es)
AR (1) AR057130A1 (es)
AT (1) ATE506350T1 (es)
AU (1) AU2006292849A1 (es)
BR (1) BRPI0616136A2 (es)
CA (1) CA2621062A1 (es)
DE (1) DE602006021440D1 (es)
EC (1) ECSP088375A (es)
IL (1) IL189857A0 (es)
NO (1) NO20081862L (es)
RU (1) RU2008110914A (es)
TW (1) TW200800902A (es)
UY (1) UY29805A1 (es)
WO (1) WO2007035158A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940795A1 (en) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
KR20090122253A (ko) * 2007-03-19 2009-11-26 아스트라제네카 아베 퀴놀린 유도체, 이를 포함하는 제약 조성물, 및 중추신경계 및 말초 질환의 치료에서의 이의 용도
DK2139882T3 (en) * 2007-03-23 2014-03-10 Amgen Inc 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699319B2 (en) 1994-05-27 1998-12-03 Smithkline Beecham Farmaceutici S.P.A. Quinoline derivatives as tachykinin nk3 receptor antagonists
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
GB9502644D0 (en) 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9513118D0 (en) 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
SK66798A3 (en) 1995-11-24 1999-01-11 Smithkline Beecham Spa Quinoline derivative, preparation method thereof, pharmaceutical composition containing the same and its use
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
PL336942A1 (en) 1997-05-23 2000-07-17 Smithkline Beecham Spa Derivatives of quinoline-4-carboxamide as antagonists of nk-2 and nk-3 receptor
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
BR9915475A (pt) 1998-11-20 2001-12-18 Smithkline Beecham Spa Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
GB0027701D0 (en) 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
AU2002226356A1 (en) 2000-11-28 2002-06-11 Glaxosmithkline S.P.A. Quinoline derivatives as nk-3 antagonists
JP2004519432A (ja) 2000-11-28 2004-07-02 グラクソスミスクライン・ソシエタ・ペル・アチオニ 新規化合物
EP1659120A1 (en) 2001-04-11 2006-05-24 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
GB0109122D0 (en) 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
WO2006137789A1 (en) 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as NK3 receptor modulators
EP1940795A1 (en) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
WO2007039123A2 (en) 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
US20080275082A1 (en) 2005-09-30 2008-11-06 Jeffrey Brum Pharmaceutical Composition

Also Published As

Publication number Publication date
UY29805A1 (es) 2007-04-30
AR057130A1 (es) 2007-11-14
RU2008110914A (ru) 2009-10-27
NO20081862L (no) 2008-06-16
BRPI0616136A2 (pt) 2011-06-07
ATE506350T1 (de) 2011-05-15
AU2006292849A1 (en) 2007-03-29
US20080214605A1 (en) 2008-09-04
IL189857A0 (en) 2008-08-07
EP1928835A1 (en) 2008-06-11
EP1928835B1 (en) 2011-04-20
US7964733B2 (en) 2011-06-21
WO2007035158A1 (en) 2007-03-29
JP2009508946A (ja) 2009-03-05
CA2621062A1 (en) 2007-03-29
DE602006021440D1 (de) 2011-06-01
TW200800902A (en) 2008-01-01
KR20080046669A (ko) 2008-05-27

Similar Documents

Publication Publication Date Title
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
GT200600518A (es) Derivados de pirimidina
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31524A1 (es) Nuevos compuestos 010
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
CR10148A (es) Derivados de las benzamidas y heteroarenos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY29486A1 (es) Compuestos utiles en terapia
ECSP088549A (es) Nuevos derivados de pirrol fusionado
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR055616A1 (es) Compuestos de tiofeno bencimidazol
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY31071A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones